From: Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
Drug | Patients distribution | Response (ORR, DOR, CR) | Phase |
---|---|---|---|
Chidamide [54] | N = 79 PTCL-NOS (34%), ALCL (20%), ENKTL: (20%) | ORR:28% Median PFS: 2.1 months OS:21.4 months CR/Cru:14% Median DOR: 9.9 month | II |
Chidamide-Combined Chemotherapy [56] | N = 127 | ORR = 51.18% DCR = 74.02% Median PFS = 152 day | II |
Chidamide [56] | N = 383 PTCL monotherapy (n = 256) | Monotherapy ORR = 39.06% DCR = 64.45%, median (PFS) = 129 days | II |
Vorinostat [60] combination with chop | N = 14 | Median PFS = 79% OS = 82% Median response duration = 29 months | I |
N = 130 | ORR = 25% CR/Cru = 15% median PFS = 13.4 ~ 29 months. median DOR = 28 months | II | |
Romidepsin [68] | N = 47 PTCL | ORR = 38%,CR = 18% median DOR = 8.9 months | II |
Romidepsin plus chop [70] | N = 37 | ORR = 69% PFS = 41% OS = 71%, | Ib/II |
Pralatrexate + Romidepsin [72] | N = 29 | ORR = 71% (10/14) | II |
Romidepsin [73] | N = 27 AITL | ORR = 33% |  |
Belinostat [74] | N = 24 PTCL | ORR = 25%, CR = 8%, DOR = 13.6mo | II |
N = 129 | ORR (CR, PR) = 25.8% Median DoR = 13.6 months Median PFS = 1.6 months Median OS = 7.9 months | II | |
N = 12 | ORR = 75%, median PFS = 15 months median OS = 21 months | Clinic trial |